IL6 and COVID-19: Nevertheless, IL-6-blocking substances must not be seen as the final key treatments to combat COVID-19, as IL-6 is not solely responsible for the cytokine storm in COVID-19 because it still remains unclear whether elevated IL-6 in viral infections, and SARS-CoV-2 in particular, represents a therapeutic target or part of a functioning adaptive immune response.